|
End-of-day quote
Korea S.E.
11/09/2026
|
5-day change | 1st Jan Change | ||
| 3,250.00 KRW | -1.52% |
|
-5.39% | -52.76% |
| 13/04 | Genome & Company announced that it has received KRW 6.99999414 billion in funding | CI |
| 03/04 | Genome & Company announced that it expects to receive KRW 6.99999414 billion in funding | CI |
Company Valuation: Genome & Company
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 10,48,465 | 4,68,827 | 2,45,897 | 1,76,209 | 85,207 | 2,38,384 |
| Change | - | -55.28% | -47.55% | -28.34% | -51.64% | 179.77% |
| Enterprise Value (EV) 1 | 9,40,636 | 3,98,490 | 1,45,490 | 1,16,390 | 36,301 | 2,20,521 |
| Change | - | -57.64% | -63.49% | -20% | -68.81% | 507.48% |
| P/E | -24.9x | -13.7x | -4.74x | -3.72x | -4.17x | -33.5x |
| PBR | 9.49x | 5.26x | 2.55x | 2.98x | 1.8x | 2.36x |
| PEG | - | 0.7x | -0.1x | 0.43x | 0.1x | 0.5x |
| Capitalization / Revenue | 6,963x | 1,039x | 17.5x | 12.3x | 3.07x | 9.7x |
| EV / Revenue | 6,247x | 883x | 10.3x | 8.14x | 1.31x | 8.97x |
| EV / EBITDA | -37.4x | -11.9x | -3.03x | -2.49x | -2.17x | -9.77x |
| EV / EBIT | -35.3x | -11x | -2.53x | -2.11x | -1.5x | -7.54x |
| EV / FCF | -12.3x | -23.3x | -4.12x | -3.7x | -2.08x | -10.3x |
| FCF Yield | -8.16% | -4.3% | -24.3% | -27% | -48% | -9.74% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -1,596 | -1,269 | -1,842 | -1,681 | -660.2 | -205.3 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | 150.6 | 451.2 | 14,085 | 14,296 | 27,745 | 24,587 |
| EBITDA 1 | -25,164 | -33,496 | -48,051 | -46,820 | -16,752 | -22,563 |
| EBIT 1 | -26,629 | -36,087 | -57,512 | -55,092 | -24,199 | -29,234 |
| Net income 1 | -30,732 | -34,117 | -51,838 | -47,466 | -20,112 | -6,428 |
| Net Debt 1 | -1,07,829 | -70,338 | -1,00,408 | -59,819 | -48,906 | -17,862 |
| Reference price 2 | 39,750.00 | 17,350.00 | 8,725.00 | 6,245.00 | 2,750.00 | 6,880.00 |
| Nbr of stocks (in thousands) | 26,376 | 27,022 | 28,183 | 28,216 | 30,984 | 34,649 |
| Announcement Date | 10/03/21 | 21/03/22 | 21/03/23 | 20/03/24 | 20/03/25 | 20/03/26 |
1KRW in Million2KRW
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 13Cr | |
| 31.04x | 5.6x | 16.76x | 1.05% | 4.55TCr | |
| -20.85x | 240.83x | -22.36x | -.--% | 4.37TCr | |
| 33.71x | 3.27x | 14.1x | -.--% | 4.31TCr | |
| 45.39x | 5.23x | 28.64x | -.--% | 3.94TCr | |
| 27.03x | 8.15x | 20.66x | 0.42% | 3.19TCr | |
| 33.41x | 5.47x | 24.85x | -.--% | 1.64TCr | |
| 23.57x | 2.06x | 8.94x | 1.13% | 1.42TCr | |
| 74.44x | 3.94x | 15.27x | -.--% | 1.33TCr | |
| Average | 30.97x | 34.32x | 13.36x | 0.33% | 2.75TCr | |
| Weighted average by Cap. | 26.17x | 46.68x | 11.79x | 0.31% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- A314130 Stock
- Valuation Genome & Company
Select your edition
All financial news and data tailored to specific country editions
